logo logo logo

Discover ~4-year efficacy and safety data for UC with JYSELECA®
▼(filgotinib)

The long-term efficacy and safety profile of JYSELECA in UC patients are being assessed in the ongoing SELECTIONLTE study, a non-randomised extension of the SELECTION study, involving 1173 participants who had previously enrolled in a JYSELECA treatment study for UC. New data from the interim analysis show that JYSELECA maintains symptom improvement, demonstrates a manageable safety profile, and maintains HRQoL up to ~4 years, further supporting its potential as a treatment option for patients with moderately to severely active UC.1*

doctor

Meet
the expert 

Dr. Brian Feagan
Dr. Brian Feagan

Professor of Medicine, Epidemiology and Biostatistics at Western University, Canada, and lead investigator of the SELECTION trials. His research focuses on the development, validation, and optimisation of outcome measures to assess the efficacy of therapeutics in irritable bowel disease (IBD), with a specific focus on the design and execution of large-scale randomized controlled trials (RCTs). Over the past 30 years, Dr. Feagan has been the principal investigator in over 140 RCTs.
In this video, Dr. Feagan discusses highlights from the SELECTIONLTE study  
video-preview

View
the abstract

Interim results from the SELECTIONLTE study show that JYSELECA maintains symptom improvement and HRQoL from baseline for up to ~ 4 years.1
YOU CAN DOWNLOAD THE STUDY RESULTS HERE

Stay
connected 

This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.
This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.
This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.
This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.

* JYSELECA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent2

IBD, Irritable bowel disease; HRQoL, Health related quality of life; RCT, Randomised controlled trial; UC, Ulcerative colitis.

 

REFERENCES

1. Feagan BG et al. Abstract presented at ECCO 2023: OP35. 2. JYSELECA Summary of Product Characteristics, February 2023.

[Insert prescribing information] 

[Insert prescribing information] 

galapagos-health galapagos-health galapagos-health

JYSELECA, GALAPAGOS
and the GALAPAGOS logo are registered
trademarks of Galapagos NV.
© 2022 Galapagos NV.
All rights reserved. 

GL-UC-JY-202303-00005 04/23

Popular Pages 
Other Categories 
Follow us here too 
galapagos-health galapagos-health galapagos-health

JYSELECA, GALAPAGOS
and the GALAPAGOS logo are registered
trademarks of Galapagos NV.
© 2022 Galapagos NV.
All rights reserved. 

GL-UC-JY-202303-00005 04/23

Privacy notice
Terms of use
Site map
Disclaimer

© Copyright 2023 Galapagos NV